Author of

• 12544

  +

  P3.08 - Poster Session 3 - Radiotherapy (ID 199)

  • Event: WCLC 2013
  • Type: Poster Session
  • Track: Radiation Oncology + Radiotherapy
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/30/2013, 09:30 - 16:30, Exhibit Hall, Ground Level

  • 12545

    +

    P3.08-001 - Feasibility of stereotactic body radiation therapy with concurrent chemotherapy for patients over 75 years old with Stage I non-small-cell lung cancer. (ID 241)

    09:30 - 09:30  |  Author(s): N. Ueki
    • Abstract

    Background
    Stereotactic body radiation therapy (SBRT) is now the standard treatment for elderly patients with inoperable Stage I non-small-cell lung cancer (NSCLC). However SBRT with concurrent chemotherapy may be feasible and effective to selected elderly patients with NSCLC. This retrospective study was aimed to evaluate the safety and tolerability of concurrent SBRT and chemotherapy in patients aged 75 years or older.

    Methods
    We reviewed the records of 11 NSCLC patients who were 75 years or older when treated with SBRT and concurrent chemotherapy with curative intent from 2009 to 2012. Five patients had T1 tumor, the others had T2 tumors. The median age was 81 years with a range of 76 to 88 years. Eight (72%) patients had chronic obstructive pulmonary disease. The median number of Eastern Cooperative Oncology Group (ECOG) performance status of the cases in the beginning of treatment was 1 with a range from 0 to 2. The median delivered radiation dose was 48 Gy in 4 fractions. Concurrent chemotherapy regimen was carboplatin plus paclitaxel, carboplatin plus docetaxel, paclitaxel alone, pemetrexed alone, and S1 alone.

    Results
    All patients received SBRT on schedule. Out of 11 patients, concurrent chemotherapy was successfully accomplished as originally planned in 8 (72%) patients. Initial effect of SBRT plus chemotherapy could be evaluated in all cases. Complete local remission was achieved in 10 patients. One patient alone had local recurrence. Distant metastases observed in 4 patients. In 2 patients, chemotherapy was intermitted due to grade 3 neutrophil count decreased and anemia (Common Terminology Criteria for Adverse Events version 4.0). In another, chemotherapy was broken off because of Grade 2 radiation pneumonitis. During the treatment, no other adverse event was shown. No treatment-related death was observed.

    	Grade 2	Grade 3
    Neutrophil count decreased	6 (55%)	1 (9%)
    Anemia	1 (9%)	2 (10%)
    Radiation pneumonitis	1 (9%)	0

    Conclusion
    SBRT plus concurrent chemotherapy might be feasible in selected patients aged 75 years or older with Stage I NSCLC.